Based on the clinical trial data (NCT05266105) presented at the 2023 ESMO Breast Cancer Annual Congress, the combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with ER+ MBC. Here, ESR1 is linked to breast carcinoma.